Clinical Research, Pharma & Healthcare FinancingPhase 3 MYR301: Bulevirtide Shows Sustained UndetectabilityBusiness WireMay 7, 2025May 9, 2025 by Business WireMay 7, 2025May 9, 2025035 – 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost...
